ReShape Lifesciences Inc. (RSLS)

Market Cap	5.92M
Revenue (ttm)	8.34M
Net Income (ttm)	-10.92M
Shares Out	29.39M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	518,266
Open	0.215
Previous Close	0.211
Day's Range	0.200 - 0.215
52-Week Range	0.141 - 1.510
Beta	1.39
Analysts	Hold
Price Target	n/a
Earnings Date	Aug 5, 2024

About RSLS

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual’s comfort and therapy effec...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 15, 2007
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: RSLS

Financial Performance

In 2023, RSLS's revenue was $8.68 million, a decrease of -22.79% compared to the previous year's $11.24 million. Losses were -$11.39 million, -75.36% less than in 2022.